Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer
Tongchen He(University of Michigan), Arul M. Chinnaiyan(University of Michigan), Jasmine P. Wisniewski(University of Michigan), Hanbyul Cho(University of Michigan), Bailey W. Jackson(University of Michigan), Somnath Mahapatra(University of Michigan), Chandrasekhar Abbineni(Aurigene Discovery Technologies (India)), Yu‐Sun Chang(Chang Gung University), Xuhong Cao(Howard Hughes Medical Institute), Siyu Hou(Yale University), Sandeep Dukare(Aurigene Discovery Technologies (India)), Abhijit Parolia(University of Michigan), Kiran Aithal(Aurigene Discovery Technologies (India)), Samiulla D.S(Aurigene Discovery Technologies (India)), Rahul Mannan(University of Michigan), Eleanor Young(University of Michigan), Stephanie J. Miner(University of Michigan), Fengyun Su(University of Michigan), Subhendu Mukherjee(Aurigene Discovery Technologies (India)), Ulka N. Vaishampayan(University of Michigan), Victoria Zhixuan Zeng(University of Michigan), Costas A. Lyssiotis(University of Michigan), Bilash Kuila(Aurigene Discovery Technologies (India)), Rui Wang(University of Michigan), Nam Hoon Kim(Georgia Institute of Technology), Yang Zheng(Shanghai Ninth People's Hospital), Caleb Cheng(University of Michigan), Lanbo Xiao(University of Michigan), Yuanyuan Qiao(University of Michigan)
Cited by 22
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k